A signal amplification system and a colloidal gold joint detection kit meeting four items and a preparation method thereof
Through the gold-labeled biotinylated antigen/antibody-streptavidin complex in the signal amplification system, the problem of insufficient sensitivity and specificity in infectious disease detection methods is solved, and the detection results of high accuracy and stability are achieved. Simplified operation process.
Patent Information
- Application Number
- CN202411173664.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-26
- Publication Date
- 2024-11-29
- Estimated Expiration
- 2044-08-26
AI Technical Summary
The existing infectious disease detection methods have shortcomings in terms of sensitivity, specificity, detection speed, etc., which leads to difficulty in diagnosis of early infection, high detection complexity, and the performance and stability of the kit affect the accuracy of the detection results.
Using a signal amplification system, including the first complex of gold-labeled biotinylated first antigen/antibody-strepvidine, the complex is formed through the binding of the biotinylated antigen/antibody to strepvidine, and the complex is formed and included. It is used in immunocolloidal gold pads to improve the specificity and sensitivity of the detection.
It improves the sensitivity and specificity of the detection, simplifies the operation process, enhances the accuracy of the detection results and the stability of the kit, and ensures the repeatability and long-term stability of the detection performance.
Smart Images

Figure SMS_1 
Figure SMS_2 
Figure SMS_3
Abstract
Description
Technical Field
[0001] The invention belongs to the field of immunoassay, and specifically relates to a signal amplification system and a colloidal gold joint detection kit that meets four items and a preparation method thereof. Background Art
[0002] The four infectious diseases generally include HIV, hepatitis C virus, syphilis and hepatitis B virus. These four diseases are infectious diseases that can be transmitted through sex and blood. AIDS antibodies (HIV antibodies) are specific antibodies produced by the immune system under viral stimulation after the body is infected with HIV. This antibody only exists in HIV-infected people and can be used as a basis for diagnosing HIV infection. In addition, P24 antigen is a protein on HIV particles, also known as core protein. When the human body is infected with HIV, the virus enters the human cells and reproduces by replicating its own genetic material. In this process, the virus releases some viral core particles, which contain P24 protein. Detecting human immunodeficiency virus P24 antigen and antibodies can help diagnose HIV infection. Hepatitis C virus antibodies (HCV antibodies) are markers that appear in the body after infection with hepatitis C virus. They are non-protective antibodies, that is, their presence cannot protect the body from HCV reinfection. HCV antibodies are an important indicator for diagnosing hepatitis C. Syphilis antibodies refer to a protein with immune function produced by the body's immune system against spirochetes after the human body is infected with Treponema pallidum. Syphilis antibodies are divided into two types: specific antibodies and non-specific antibodies. A positive specific antibody test usually indicates that the patient is infected or has been infected with syphilis, and is a diagnostic indicator of syphilis infection. Non-specific antibody testing can determine the disease activity and treatment effect of syphilis, but its results are easily affected by other factors, such as pregnancy, autoimmune diseases, etc., and false positives or false negatives may occur. Hepatitis B surface antigen (HBsAg) is the outer shell protein of hepatitis B virus (HBV). Its appearance is often accompanied by the presence of hepatitis B virus, so it is one of the signs of hepatitis B virus infection. It can be found in the patient's blood, saliva, breast milk, sweat, tears, nasopharyngeal secretions, semen and vaginal secretions.
[0003] The current detection methods still have deficiencies in sensitivity, specificity, and detection speed, which makes it difficult to accurately detect some diseases. For example, the diagnosis of early infection is difficult: in the early stages of viral infection, the viral load may be very low, resulting in a negative test result, thereby delaying diagnosis and treatment. In addition, there are many types of blood diseases, and markers between different diseases may cross or overlap, which increases the difficulty and complexity of detection. Third, the detection method also requires laboratory operators to have a certain level of skills, experience, and operating specifications. Fourth, factors such as the performance, stability, and precision of the test kit may affect the accuracy of the test results; factors such as the quality, stability, and batch differences of the reagents may also affect the test results.
[0004] In order to solve these problems, it is necessary to continuously improve detection methods and technologies, improve the sensitivity and specificity of detection, strengthen the diagnosis and treatment of early infection, optimize the detection process, and obtain portable, easy-to-operate, accurate and reliable detection kits, which will help improve the accuracy and effectiveness of the four blood infectious disease tests and provide better medical services for patients. Summary of the invention
[0005] In order to solve the above problems, the present invention provides an infectious disease quadruple test kit, which improves the sensitivity and specificity of detection and has the advantages of simple operation and high accuracy of detection results.
[0006] In one aspect, the present invention provides a signal amplification system for colloidal gold detection, wherein the signal amplification system comprises a first complex of a gold-labeled biotinylated first antigen / antibody-streptavidin.
[0007] The preparation method of the signal amplification system is as follows:
[0008] (1) Preparation of biotinylated primary antigen / antibody;
[0009] (2) labeling the biotinylated first antigen / antibody obtained in step (1) with colloidal gold to obtain a colloidal gold-labeled biotinylated first antigen / antibody;
[0010] (3) mixing the colloidal gold-labeled biotinylated first antigen / antibody of step (2) with streptavidin to obtain the first complex and coating it on an immunocolloidal gold pad;
[0011] (4) Coating the second antigen / antibody on the test line;
[0012] When the test object is added, it combines with the first complex through the immunocolloidal gold pad, and then forms a second complex of second antigen / antibody-test object-gold-labeled biotinylated first antigen / antibody-streptavidin on the detection line.
[0013] Specifically, the first complex in step (3) includes: a streptavidin-biotin-linked polymeric colloidal gold-labeled HIV antibody a1 complex, a streptavidin-biotin-linked polymeric colloidal gold-labeled HIV antigen a1 complex, a streptavidin-biotin-linked polymeric colloidal gold-labeled HCV antigen b1 complex, a streptavidin-biotin-linked polymeric colloidal gold-labeled syphilis antigen c1 complex, and a streptavidin-biotin-linked polymeric colloidal gold-labeled HBsAg antibody d1 complex; the streptavidin-biotin-linked polymeric colloidal gold-labeled HIV antibody a1 complex and the streptavidin-biotin-linked polymeric colloidal gold-labeled HIV antigen a1 complex share a glass cellulose membrane.
[0014] More specifically, the concentrations of the streptavidin-biotin linked polymeric colloidal gold labeled HIV antibody a1 complex, the streptavidin-biotin linked polymeric colloidal gold labeled HIV antigen a1 complex, the streptavidin-biotin linked polymeric colloidal gold labeled HCV antigen b1 complex, the streptavidin-biotin linked polymeric colloidal gold labeled syphilis antigen c1 complex, and the streptavidin-biotin linked polymeric colloidal gold labeled HBsAg antibody d1 complex are 1-1.5%, 2-3%, 1.5-2%, 1.5-2%, and 0.8-1.3% of the volume of the labeled colloidal gold, respectively; and the spraying amount is 2-4 μL / cm.
[0015] Preferably, the concentrations of the streptavidin-biotin linked polymeric colloidal gold labeled HIV antibody a1 complex, the streptavidin-biotin linked polymeric colloidal gold labeled HIV antigen a1 complex, the streptavidin-biotin linked polymeric colloidal gold labeled HCV antigen b1 complex, the streptavidin-biotin linked polymeric colloidal gold labeled syphilis antigen c1 complex, and the streptavidin-biotin linked polymeric colloidal gold labeled HBsAg antibody d1 complex are 1-1.2%, 2-2.5%, 1.5-1.8%, 1.5-1.8%, and 0.8-1.0% of the volume of the labeled colloidal gold, respectively; and the spraying amount is 3-4 μL / cm.
[0016] Specifically, the test line and quality control line described in step S3 include: HIV test items include T a1 、T a2 Test line and quality control line C a , respectively coated with HIV antibody a2, HIV antigen a2 and anti-biotin antibody; HCV detection items include quality control line T b and quality control line C b , respectively coated with HCV antigen b2 and anti-biotin antibody; Syphilis test items include quality control line T c and quality control line C c, respectively coated with syphilis antigen c2 and anti-biotin antibody; HBsAg detection items include quality control line T d and quality control line C d , coated with HBsAg antibody d2 and anti-biotin antibody respectively.
[0017] In yet another aspect, the present invention provides a quadruple test paper, wherein the quadruple test paper comprises four test strips.
[0018] Specifically, the test strip consists of a coating membrane, an immune colloidal gold pad, a sample pad and a water absorbent pad.
[0019] More specifically, the immunocolloidal gold pad includes a signal amplification system; the signal amplification system is the aforementioned signal amplification system.
[0020] In yet another aspect, the present invention provides the use of the aforementioned signal amplification system or quadruple test paper in the preparation of a quadruple test kit for infectious diseases.
[0021] Specifically, the infectious disease is caused by one or more pathogens selected from the group consisting of HIV, hepatitis C virus, syphilis and hepatitis B virus.
[0022] In yet another aspect, the present invention provides a kit, comprising the aforementioned quadruple test strip.
[0023] In another aspect, the present invention provides a method for preparing the aforementioned quadruple test paper, characterized in that the preparation method comprises the following steps:
[0024] S1. Preparation of sample pad: soak the glass cellulose membrane in sample pad treatment solution and dry it for later use;
[0025] S2, immunocolloidal gold pad: soak the glass cellulose membrane in the immunocolloidal gold pad treatment solution, dry it, spray it with the aforementioned signal amplification system, dry it again and set it aside;
[0026] S3, coating membrane treatment: coating the test line and quality control line on the nitrocellulose membrane;
[0027] S4. Test strip assembly: Assemble in the order of coating membrane-immunocolloidal gold pad-sample pad-absorbent pad.
[0028] Specifically, the composition of the sample pad treatment solution described in step S1 can be: 10-20mM Tris-HCl buffer, 0.2%-0.5%m / V PEG20000, 0.1%-0.8%m / V Tween-20, 0.1%-0.5%m / V sodium citrate, 2%-4%m / V sucrose, 0.3%-0.5%m / V sodium chloride, pH 8-9.
[0029] In some embodiments, the composition of the sample pad treatment solution described in step S1 can be: 20mM Tris-HCl buffer, 0.2%m / V PEG20000, 0.1%m / V Tween-20, 0.5%m / V sodium citrate, 4%m / V sucrose, 0.3%m / V sodium chloride, pH 8.0.
[0030] In other embodiments, the composition of the sample pad treatment solution described in step S1 can be: 10mM Tris-HCl buffer, 0.5%m / V PEG20000, 0.8%m / V Tween-20, 0.1%m / V sodium citrate, 2%m / V sucrose, 0.5%m / V sodium chloride, pH 9.0.
[0031] Specifically, the composition of the immunocolloidal gold pad treatment solution described in step S2 can be: 5-15mM Tris-HCl buffer, 0.1%-3%m / V sodium dihydrogen phosphate, 1%-3%m / V potassium chloride, 2%-5%m / V sucrose, 1%-3%m / V glucose, 1%-5%m / V BSA, 0.2%-0.5%m / V sodium lactate, 0.2%-0.5%m / V glycine, pH 7-8.
[0032] In some embodiments, the composition of the immune colloidal gold pad treatment solution described in step S2 can be: 5mM Tris-HCl buffer, 0.1% m / V sodium dihydrogen phosphate, 1% m / V potassium chloride, 2% m / V sucrose, 1% m / V glucose, 1% m / V BSA, 0.5% m / V sodium lactate, 0.2% m / V glycine, pH 7.0.
[0033] In other embodiments, the composition of the immune colloidal gold pad treatment solution described in step S2 can be: 15mM Tris-HCl buffer, 3%m / V sodium dihydrogen phosphate, 3%m / V potassium chloride, 5%m / V sucrose, 3%m / V glucose, 5%m / V BSA, 0.2%m / V sodium lactate, 0.5%m / V glycine, pH 8.0.
[0034] Specifically, the test line and quality control line described in step S3 include: HIV test items include T a1 、T a2 Test line and quality control line C a , respectively coated with HIV antibody a2, HIV antigen a2 and anti-biotin antibody; HCV detection items include quality control line T b and quality control line C b , respectively coated with HCV antigen b2 and anti-biotin antibody; Syphilis test items include quality control line T c and quality control line C c, respectively coated with syphilis antigen c2 and anti-biotin antibody; HBsAg detection items include quality control line T d and quality control line C d , coated with HBsAg antibody d2 and anti-biotin antibody respectively;
[0035] More specifically, both the test line and the quality control line are coated at 0.5-1.0 mg / mL.
[0036] Preferably, both the test line and the quality control line are coated at 0.8-1.0 mg / mL.
[0037] Further preferably, the test line and the quality control line are coated at 0.8 mg / mL.
[0038] Technical effects achieved by the present invention: The present invention provides a new signal amplification system, which improves the specificity of detection by coating a gold-labeled biotinylated first antigen / antibody-streptavidin first complex. In addition, the present invention also provides an immunocolloidal gold pad treatment solution, and the sodium lactate and glycine in the immunocolloidal gold pad treatment solution also have a synergistic effect, which further improves the detection performance. The infectious disease quadruple detection kit prepared using the signal amplification system and immunocolloidal gold pad treatment solution provided by the present invention also has strong repeatability and long-term stability, and can be stored at room temperature for 36 months and still has excellent detection performance. DETAILED DESCRIPTION
[0039] The present invention will be further described in detail below in conjunction with specific examples. The following examples are not intended to limit the present invention, but are only intended to illustrate the present invention. The experimental methods used in the following examples are generally conventional, unless otherwise specified, and the materials, reagents, etc. used in the following examples are commercially available, unless otherwise specified.
[0040] The source information of some reagents in the examples of the present invention is shown in Table 1.
[0041] Table 1 Main reagents
[0042]
[0043] Example 1
[0044] 1.1 Reagent formulation
[0045] (1) Sample pad treatment solution formula: 20 mM Tris-HCl buffer, 0.2% m / V PEG20000, 0.1% m / V Tween-20, 0.5% m / V sodium citrate, 4% m / V sucrose, 0.3% m / V sodium chloride, pH 8.
[0046] (2) Formula of immunocolloidal gold pad treatment solution: 5 mM Tris-HCl buffer, 0.1% m / V sodium dihydrogen phosphate, 1% m / V potassium chloride, 2% m / V sucrose, 1% m / V glucose, 1% m / V BSA, 0.5% m / V sodium lactate, 0.2% m / V glycine, pH 7.
[0047] 1.2 Preparation of signal amplification system
[0048] (1) Preparation of biotinylated HIV antibody a1, HIV antigen a1, HCV antigen b1, syphilis antigen c1, and HBsAg antibody d1
[0049] First, 6-aminohexose is used to connect biotin to obtain long-arm biotin, and then it is combined with HIV antibody a1, HIV antigen a1, HCV antigen b1, syphilis antigen c1, and HBsAg antibody d1 respectively, and then it is condensed with N-hydroxysuccinamide under the action of carbodiimide to generate long-arm biotin N-hydroxysuccinamide ester, that is, biotinylated HIV antibody a1, biotinylated HIV antigen a1, biotinylated HCV antigen b1, biotinylated syphilis antigen c1, and biotinylated HBsAg antibody d1, and free biotin is removed by dialysis.
[0050] (2) Preparation of biotinylated gold label
[0051] The biotinylated HIV antibody a1, biotinylated HIV antigen a1, biotinylated HCV antigen b1, biotinylated syphilis antigen c1, and biotinylated HBsAg antibody d1 to be labeled are dialyzed overnight in a 0.001-0.01 mol / L (not 0.005 mol / L in the embodiment of the present invention) sodium chloride solution, centrifuged, and the pH of the colloidal gold is adjusted to 9-10 for labeling to form colloidal gold labeled biotinylated HIV antibody a1, biotinylated HIV antigen a1, biotinylated HCV antigen b1, biotinylated syphilis antigen c1, and biotinylated HBsAg antibody d1. The ratio of the biotinylated HIV antibody a1, biotinylated HIV antigen a1, biotinylated HCV antigen b1, biotinylated syphilis antigen c1, and biotinylated HBsAg antibody d1 to the colloidal gold is (10-20) μg:1 mL, and in this embodiment it is 15 μg:1 mL.
[0052] (3) Adding a signal amplification system
[0053] The recombinant streptavidin at 0.4 μg / mL was mixed with the colloidal gold-labeled biotinylated HIV antibody a1, biotinylated HIV antigen a1, biotinylated HCV antigen b1, biotinylated syphilis antigen c1, and biotinylated HBsAg antibody d1 obtained in step (2), respectively, and reacted for 30-60 minutes (40 minutes in this embodiment) to obtain a streptavidin-biotin-linked polymeric colloidal gold-labeled HIV antibody a1 complex, a streptavidin-biotin-linked polymeric colloidal gold-labeled HIV antigen a1 complex, a streptavidin-biotin-linked polymeric colloidal gold-labeled HCV antigen b1 complex, a streptavidin-biotin-linked polymeric colloidal gold-labeled syphilis antigen c1 complex, and a streptavidin-biotin-linked polymeric colloidal gold-labeled HBsAg antibody d1 complex.
[0054] After signal amplification, the core of this amplification system does not change the "double antibody / double antigen sandwich" formed between the stationary phase (coating membrane) and the mobile phase (gold label pad), which can maintain the specificity of the original sandwich method to the greatest extent and reduce the impact of biotin substances in the sample on the test results.
[0055] 1.3 Preparation of colloidal gold combined detection kit
[0056] The colloidal gold joint detection kit of the present invention comprises 4 detection test strips, each of which is sequentially and mutually staggered 2mm with a coating film, an immune colloidal gold pad, a sample pad and a water-absorbing pad on a plastic bottom plate to obtain a test paper board, which is cut according to the required width to obtain the test strip.
[0057] 1.3.1 Sample pad
[0058] Immerse the glass cellulose membrane in the sample pad treatment solution for 12 minutes, dry it at 37°C for 8-16 hours and set aside. The treatment method of the sample pads of the four test strips is the same.
[0059] 1.3.2 Immunocolloidal gold pad
[0060] The glass cellulose membrane was immersed in the immunocolloidal gold pad treatment solution for 10 minutes and dried at 37°C. Then, the five signal amplification systems labeled with colloidal gold were coated on four glass cellulose membranes respectively and dried at 37°C for later use. The concentration of the streptavidin-biotin linked polymer colloidal gold labeled HIV antibody a1 complex is 1-1.5% (1.2% in this embodiment); the concentration of the streptavidin-biotin linked polymer colloidal gold labeled HIV antigen a1 complex is 2-3% (2.5% in this embodiment); the concentration of the streptavidin-biotin linked polymer colloidal gold labeled HCV antigen b1 complex is 1.5-2% (1.8% in this embodiment); the concentration of the streptavidin-biotin linked polymer colloidal gold labeled syphilis antigen c1 complex is 1.5-2% (1.8% in this embodiment); the concentration of the streptavidin-biotin linked polymer colloidal gold labeled HBsAg antibody d1 complex is 0.8-1.3% of the volume of the labeled colloidal gold (1.0% in this embodiment). The streptavidin-biotin linked polymeric colloidal gold labeled HIV antibody a1 complex and the streptavidin-biotin linked polymeric colloidal gold labeled HIV antigen a1 complex share a glass cellulose membrane; the spraying amount is 2-4 μL / cm (3 μL / cm in this embodiment).
[0061] 1.3.3 Coating membrane
[0062] The test lines and quality control lines were coated on 4 nitrocellulose membranes (NC membranes), and the HIV test items included T a1 、T a2 Test line and quality control line C a , respectively coated with HIV antibody a2, HIV antigen a2 and anti-biotin antibody; HCV detection items include quality control line T b and quality control line C b , respectively coated with HCV antigen b2 and anti-biotin antibody; Syphilis test items include quality control line T c and quality control line C c , respectively coated with syphilis antigen c2 and anti-biotin antibody; HBsAg detection items include quality control line T d and quality control line C d , coated with HBsAg antibody d2 and anti-biotin antibody respectively. The test line was coated with 0.8 mg / mL, and the quality control line was coated with 0.8 mg / mL.
[0063] 1.3.4 Test strip assembly
[0064] The coating membrane, immune colloidal gold pad, sample pad and water-absorbing pad are assembled on the bottom plate in sequence, and the test strips are obtained by cutting according to the required width.
[0065] 1.4 Result determination
[0066] (1) HIV testing: T a1 and / or T a2 Displays red, the test result is positive, indicating possible HIV infection, and needs to be retested or further "supplementary test"; T a1 and T a2 If there is no red strip, the test result is negative, indicating that there is no HIV infection; if there is no strip in the quality control area, it means that the test strip is invalid and the test line result is invalid.
[0067] (2) HCV testing: T b Displays red, the test result is positive, indicating HCV infection; T b If there is no red strip, the test result is negative, indicating that there is no HCV infection; if there is no strip in the quality control area, it means that the test strip is invalid and the test line result is invalid.
[0068] (3) Syphilis test: T c Displays red, the test result is positive, indicating syphilis infection; T c If there is no red strip, the test result is negative, indicating that there is no syphilis infection; if there is no strip in the quality control area, it means that the test strip is invalid and the test line result is invalid.
[0069] (4) HBsAg detection: T d Displays red, the test result is positive, indicating HBsAg infection; T d If there is no red strip, the test result is negative, indicating that there is no HBsAg infection; if there is no strip in the quality control area, it means that the test strip is invalid and the test line result is invalid.
[0070] Example 2
[0071] The difference between Example 2 and Example 1 is the formula of the sample pad treatment solution and the formula of the immune colloidal gold pad treatment solution, and the rest is the same as Example 1.
[0072] (1) Sample pad treatment solution formula: 10 mM Tris-HCl buffer, 0.5% m / V PEG20000, 0.8% m / V Tween-20, 0.1% m / V sodium citrate, 2% m / V sucrose, 0.5% m / V sodium chloride, pH 9.
[0073] (2) Formula of immunocolloidal gold pad treatment solution: 15 mM Tris-HCl buffer, 3% m / V sodium dihydrogen phosphate, 3% m / V potassium chloride, 5% m / V sucrose, 3% m / V glucose, 5% m / V BSA, 0.2% m / V sodium lactate, 0.5% m / V glycine, pH 8.
[0074] Comparative Example 1
[0075] Comparative Example 1 is set with reference to Example 1. The difference between Comparative Example 1 and Example 1 is that:
[0076] Preparation of signal amplification system:
[0077] (1) HIV antibody a1, HIV antigen a1, HCV antigen b1, syphilis antigen c1, and HBsAg antibody d1 are respectively labeled with gold particles to form gold-labeled HIV antibody a1, HIV antigen a1, HCV antigen b1, syphilis antigen c1, and HBsAg antibody d1 as T-line gold markers; rabbit IgG antibody is labeled with gold particles to form gold-labeled rabbit IgG antibody as C-line marker.
[0078] (2) Biotinylated HIV antibody a2, biotinylated HIV antigen a2, biotinylated HCV antigen b2, biotinylated syphilis antigen c2, and biotinylated HBsAg antibody d2 were sprayed on 5 sample pads, respectively. Gold-labeled HIV antibody a1, HIV antigen a1, HCV antigen b1, syphilis antigen c1, and HBsAg antibody d1 were combined with gold-labeled rabbit IgG antibody and sprayed on 5 glass cellulose membranes treated with gold-labeled pad treatment solution. Streptavidin was coated on the T line, and goat anti-rabbit IgG antibody was coated on the quality control line C line.
[0079] (3) When the sample is added to the sample pad, the target in the sample binds to the biotinylated HIV antibody a2 or HIV antigen a2 or biotinylated HCV antigen b2 or biotinylated syphilis antigen c2 or biotinylated HBsAg antibody d2 to form biotinylated HIV antibody a2-target or biotinylated HIV antigen a2-target or biotinylated HCV antigen b2-target or biotinylated syphilis antigen c2-target or biotinylated HBsAg antibody d2-target. With the capillary action, the complex moves to the gold-labeled pad and binds to the gold-labeled HIV antibody a1, HIV antigen a1, HCV antigen b1, syphilis antigen c1, HBsAg antibody d1 to form biotin HIV antibody a2-target-HIV antibody a1 or biotinylated HIV antigen a2-target-gold-labeled HIV antigen a1 or biotinylated HCV antigen b2-target-gold-labeled biotinylated HCV antigen b1 or biotinylated syphilis antigen c2-target-gold-labeled syphilis antigen c1 or biotinylated HBsAg antibody d2-target-gold-labeled HBsAg antibody d1 (complex). Under the same force, the complex migrates to the NC membrane and binds to the coated streptavidin. One streptavidin can bind to 4 biotin antibodies to form a tetramer to achieve signal amplification. The C-line marker continues to migrate to the quality control line C line position and binds to the goat anti-rabbit IgG antibody coated on the C line.
[0080] The difference between the embodiment of the present invention and the signal amplification system in the prior art is that:
[0081] In the embodiment of the present invention, the detection line (T line) is coated with the second antigen / antibody, and finally a complex of the second antigen / antibody-test object-gold-labeled biotinylated first antigen / antibody-streptavidin is formed from bottom to top;
[0082] In the prior art, the detection line (T line) is coated with streptavidin, and finally a complex of streptavidin-biotinylated first antigen / antibody-test object-gold-labeled second antigen / antibody is formed from bottom to top.
[0083] Comparative Examples 2-4 are set with reference to Example 1. The differences between Comparative Examples 2-4 and Example 1 are shown in Table 2.
[0084] Table 2 The difference between Comparative Examples 2-4 and Example 1
[0085]
[0086] Experimental example
[0087] 1. Sensitivity
[0088] The kits of the embodiments and comparative examples were used to detect HIV P24 antigen, HIV antibody, HCV antibody, syphilis antibody, and HBsAg of different concentrations or COI values (wherein HIV P24 antigen and HBsAg were from commercially available NIBSC international reference materials, and HIV antibody, HCV antibody, and syphilis antibody were from positive clinical samples of the corresponding test items), all of which were diluted with negative serum / plasma. Each concentration or COI value was tested once, and the concentrations or COI values tested and the test results are shown in Tables 3-7.
[0089] Table 3 HIV P24 antigen sensitivity test results
[0090]
[0091] Note: “+” indicates a positive test result, and “-” indicates a negative test result.
[0092] Table 4 HIV antibody sensitivity test results
[0093]
[0094] Note: “+” indicates a positive test result, and “-” indicates a negative test result.
[0095] Table 5 HCV antibody sensitivity test results
[0096]
[0097] Note: “+” indicates a positive test result, and “-” indicates a negative test result.
[0098] Table 6 Syphilis antibody sensitivity test results
[0099]
[0100] Note: “+” indicates a positive test result, and “-” indicates a negative test result.
[0101] Table 7 HBsAg antigen sensitivity test results
[0102]
[0103] Note: “+” indicates a positive test result, and “-” indicates a negative test result.
[0104] 2. Clinical sample verification
[0105] The kits of the embodiments and comparative examples were used to test 1000 clinical samples that were negative for HIV antibody, HIV P24 antigen, HCV antibody, syphilis antibody and HBsAg, and 500 clinical samples that were positive for HIV antibody, 25 clinical samples that were positive for HIV P24 antigen, 500 clinical samples that were positive for HCV antibody, 500 clinical samples that were positive for syphilis antibody and 500 clinical samples that were positive for HBsAg.
[0106] Each sample was tested once, and the test results are shown in Table 8. Positive samples: sensitivity = number of positive samples detected / total number of positive samples; negative samples: specificity = number of negative samples detected / total number of negative samples.
[0107] Table 8 Specificity test results
[0108]
[0109] (1) Specificity of negative syphilis antibody: 99.9% for Example 1, 99.7% for Example 2, 85.3% for Comparative Example 1, 91.2% for Comparative Example 2, 92.2% for Comparative Example 3, and 90.1% for Comparative Example 4;
[0110] The sensitivity of positive syphilis antibody: Example 1 is 100%, Example 2 is 100%, Comparative Example 1 is 99, Comparative Example 2 is 93%, Comparative Example 3 is 90.6%, and Comparative Example 4 is 88.2%.
[0111] (2) Specificity of HIV antibody and HIV P24 antigen negative: 99.8% for Example 1, 99.6% for Example 2, 84.2% for Comparative Example 1, 89.5% for Comparative Example 2, 90.7% for Comparative Example 3, and 87.5% for Comparative Example 4;
[0112] The sensitivity of HIV antibody positivity is as follows: Example 1 is 100%, Example 2 is 100%, Comparative Example 1 is 97.6%, Comparative Example 2 is 95.8%, Comparative Example 3 is 92%, and Comparative Example 4 is 89.4%.
[0113] The sensitivity of HIV P24 antigen positivity is as follows: Example 1 is 100%, Example 2 is 100%, Comparative Example 1 is 80%, Comparative Example 2 is 84%, Comparative Example 3 is 76%, and Comparative Example 4 is 68%.
[0114] (3) Specificity of HBsAg negative: 99.9% for Example 1, 99.8% for Example 2, 78.9% for Comparative Example 1, 93.2% for Comparative Example 2, 92.4% for Comparative Example 3, and 89.9% for Comparative Example 4;
[0115] The sensitivity of HBsAg positivity: Example 1 is 100%, Example 2 is 100%, Comparative Example 1 is 95.8%, Comparative Example 2 is 96%, Comparative Example 3 is 97.6%, and Comparative Example 4 is 94%.
[0116] (4) Specificity of HCV antibody negative: 99.6% for Example 1, 99.6% for Example 2, 81.2% for Comparative Example 1, 90.1% for Comparative Example 2, 87.9% for Comparative Example 3, and 89.0% for Comparative Example 4;
[0117] The sensitivity of HCV antibody positivity is as follows: Example 1 is 100%, Example 2 is 100%, Comparative Example 1 is 98.2%, Comparative Example 2 is 94.2%, Comparative Example 3 is 97.4%, and Comparative Example 4 is 90.6%.
[0118] The results in Tables 3-8 show that: According to the results of Example 1 and Comparative Examples 1-4, the signal amplification system and immune colloidal gold pad treatment solution provided by the present invention improve the detection performance of the four infectious diseases, and the sodium lactate and glycine in the treatment solution have a coordinated synergistic effect. The kit provided by the present invention has good sensitivity, sensitivity and specificity in the detection of AIDS, hepatitis C, syphilis and hepatitis B diseases, and its detection performance is significantly better than that of Comparative Examples 1-4.
[0119] 3. Reproducibility
[0120] The kits of the embodiments and comparative examples were used to detect samples S1-S3 respectively, wherein samples S1-S2 were derived from the test samples in the sensitivity of the experimental example, and S1 corresponded to the following in the sensitivity test: 5 IU / mL of P24 antigen, HIV antibody with COI value = 3.5, HCV antibody with COI value = 2.6, syphilis antibody with COI value = 3.2, and HBsAg antigen with 5 IU / mL; S2 corresponded to the following in the sensitivity test: 1.25 IU / mL of P24 antigen, HIV antibody with COI value = 1.2, HCV antibody with COI value = 1.25, syphilis antibody with COI value = 1.22, and HBsAg antigen with 1.2 IU / mL; S3 were derived from the corresponding negative clinical samples in the clinical sample verification of the experimental example; each sample was tested 10 times, and the test results are shown in Table 9, C0 represents no color development as a negative result, C1-C5 represent positive results, and the larger the number, the stronger the color development.
[0121] Table 9 Reproducibility test results of human immunodeficiency virus antigen and antibody
[0122]
[0123] Table 9: Results of reproducibility test of human immunodeficiency virus antigen and antibody
[0124]
[0125] Table 10 Hepatitis C virus antibody reproducibility test results
[0126]
[0127] Table 11 Results of reproducibility test of Treponema pallidum antibody
[0128]
[0129] Table 12 Hepatitis B virus surface antigen reproducibility test results
[0130]
[0131] The results in Tables 9 to 12 indicate that the signal amplification system and immunocolloidal gold pad treatment solution of Examples 1-2 of the present invention improve the repeatability of detection, and the sodium lactate and glycine in the immunocolloidal gold pad treatment solution still have a synergistic effect in improving repeatability, and the effect is significantly better than that of Comparative Examples 2-4.
[0132] 4. Long-term stability
[0133] The kits of the embodiment and the comparative example were stored at 25°C for 36 months, and the samples S1-S3 were tested at 10 times using the kits of the embodiment and the comparative example, wherein the samples S1-S3 were all from the test samples in the reproducibility of the experimental example. The test time and results are shown in Table 10.
[0134] Table 13 Human immunodeficiency virus antigen and antibody stability test results
[0135]
[0136] Table 13 Human immunodeficiency virus antigen and antibody stability test results
[0137]
[0138] Table 14 Hepatitis C virus antibody stability test results
[0139]
[0140] Table 15 Treponema pallidum antibody stability test results
[0141]
[0142] Table 16 Hepatitis B virus surface antigen stability test results
[0143]
[0144] The results in Tables 13-16 show that the kits of Examples 1-2 of the present invention have long-term stability, and the shelf life at room temperature can be up to 36 months, while the shelf life of Comparative Examples 1-4 is only 24-30 months. Therefore, the kit for the four-in-one detection of infectious diseases provided by Examples 1-2 of the present invention not only has the advantages of low sensitivity, strong specificity, and high sensitivity, but also can maintain excellent detection performance after long-term storage.
Claims
1. A method for preparing a quadruple test strip, characterized in that: The preparation method comprises the following steps: S1. Preparation of sample pad: soak the glass cellulose membrane in sample pad treatment solution and dry it for later use; S2, immunocolloidal gold pad: soak the glass cellulose membrane in the immunocolloidal gold pad treatment solution, dry it, spray the signal amplification system, dry it again and set it aside; S3, coating membrane treatment: coating the test line and quality control line on the nitrocellulose membrane; S4, test strip assembly: assemble in the order of coating membrane-immunocolloidal gold pad-sample pad-water absorbent pad; The sample pad treatment solution in step S1 comprises: 10-20 mM Tris-HCl buffer, 0.2%-0.5% m / V PEG20000, 0.1%-0.8% m / V Tween-20, 0.1%-0.5% m / V sodium citrate, 2%-4% m / V sucrose, 0.3%-0.5% m / V sodium chloride, pH 8-9; The composition of the immunocolloidal gold pad treatment solution in step S2 is: 5-15 mM Tris-HCl buffer, 0.1%-3% m / V sodium dihydrogen phosphate, 1%-3% m / V potassium chloride, 2%-5% m / V sucrose, 1%-3% m / V glucose, 1%-5% m / V BSA, 0.2%-0.5% m / V sodium lactate, 0.2%-0.5% m / V glycine, pH 7-8; The signal amplification system described in step S2 comprises a first complex of a gold-labeled biotinylated first antigen / antibody-streptavidin; The first complex comprises: a streptavidin-biotin-linked polymer colloidal gold-labeled HIV-1 P24 antibody a1 complex, a streptavidin-biotin-linked polymer colloidal gold-labeled HIVⅠ+Ⅱ antigen a1 complex, a streptavidin-biotin-linked polymer colloidal gold-labeled HCV-1 CORE+NS3 antigen b1 complex, a streptavidin-biotin-linked polymer colloidal gold-labeled TP 15KD+17KD+47KD antigen c1 complex, and a streptavidin-biotin-linked polymer colloidal gold-labeled anti-hepatitis B surface antigen monoclonal antibody d1 complex; the streptavidin-biotin-linked polymer colloidal gold-labeled HIV-1 P24 antibody a1 complex and the streptavidin-biotin-linked polymer colloidal gold-labeled HIVⅠ+Ⅱ antigen a1 complex share a glass cellulose membrane.
2. The preparation method according to claim 1, characterized in that: The preparation method of the signal amplification system described in step S2 is: (1) Preparation of biotinylated primary antigen / antibody; (2) labeling the biotinylated first antigen / antibody obtained in step (1) with colloidal gold to obtain a colloidal gold-labeled biotinylated first antigen / antibody; (3) mixing the colloidal gold-labeled biotinylated first antigen / antibody of step (2) with streptavidin to obtain the first complex and coating it on an immunocolloidal gold pad; (4) Coating the second antigen / antibody on the test line; When the test object is added, it combines with the first complex through the immunocolloidal gold pad, and then forms a second complex of second antigen / antibody-test object-gold-labeled biotinylated first antigen / antibody-streptavidin on the detection line.
3. The preparation method according to claim 1, characterized in that: The concentrations of the streptavidin-biotin linked polymer colloidal gold labeled HIV-1 P24 antibody a1 complex, the streptavidin-biotin linked polymer colloidal gold labeled HIVⅠ+Ⅱ antigen a1 complex, the streptavidin-biotin linked polymer colloidal gold labeled HCV-1 CORE+NS3 antigen b1 complex, the streptavidin-biotin linked polymer colloidal gold labeled TP 15KD+17KD+47KD antigen c1 complex, and the streptavidin-biotin linked polymer colloidal gold labeled anti-hepatitis B surface antigen monoclonal antibody d1 complex are 1-1.5%, 2-3%, 1.5-2%, 1.5-2%, and 0.8-1.3% of the volume of the labeled colloidal gold, respectively; and the spraying amount is 2-4 μL / cm.
4. The preparation method according to claim 1, characterized in that: The test line and quality control line described in step S3 include: HIV test items include T a1 , T a2 Test line and quality control line C a , respectively coated with HIV-1 P24 antibody a2, HIVⅠ+Ⅱ antigen a2 and anti-biotin antibody; HCV detection items include quality control line T b and quality control line C b , respectively coated with HCV-1 CORE+NS3 antigen b2 and anti-biotin antibody; Syphilis detection includes quality control line T c and quality control line C c , respectively coated with TP 15KD+17KD+47KD antigen c2 and anti-biotin antibody; HBsAg detection items include quality control line T d and quality control line C d , coated with anti-HBsAg monoclonal antibody d2 and anti-biotin antibody respectively; The test line and the quality control line are coated at 0.5-1.0 mg / mL.
5. A four-in-one test strip, characterized in that: The quadruple test paper is obtained by the preparation method described in any one of claims 1 to 4.
6. Use of the preparation method according to any one of claims 1 to 4 or the quadruple test paper according to claim 5 in preparing a quadruple test kit for infectious diseases.
7. The use according to claim 6, characterized in that: The infectious disease is caused by one or more pathogens selected from the group consisting of HIV, hepatitis C virus, syphilis and hepatitis B virus.
8. A kit, characterized in that: Including the quadruple test paper described in claim 5.
Citation Information
Patent Citations
High-sensitivity colloidal gold test paper and preparation method and application thereof
CN106872690A
Joint detection test strip for monkey pox antigen, HIV1 / 2 antibody and P24 antigen and preparation method of joint detection test strip
CN116183904A
